

## **REFERENCES**

- Abdel-Aziz F, Habib M, Mohamed MK, et al. (2000):* Hepatitis C virus infection in a community in the Nile Delta. *Hepatology*, 32:111-115.
- Abdel-Wahab MF, Zakaria S and Kamal M. (1994):* High seroprevalence of hepatitis C infection among risk groups in Egypt. *Am. J. Trop. Med. Hyg*, 51(5):563-547.
- Abdi W, Millan JC and Mezey E. (1979):* Sampling variability on percutaneous liver biopsy. *Arch. Intern. Med.*; 139: 667-669.
- Adinolfi L, Utili R, Ardreana A, et al. (2001):* Serum HCV-RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. *Digestive disease and Science*, Vol. 46, No.8, pp: 1677-1683.
- Alberti A, Noventa F, Benvegna L, et al. (2002):* Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. *Ann. Intern. Med.*, 137 (12):961-4.
- Alberti A, Morsica G, Chemello L, et al. (1992):* Hepatitis C viremia and liver disease in symptom free individuals with anti HCV. *lancet*, 340:697-698.
- Aledort LM, Levine PH, Hilgartner M, et al. (1985):* A study of liver biopsies and liver disease among hemophiliacs: *Blood*; 66:367.
- Alter MJ, Hadler SC, Judson FN, et al. (1990):* Risk factors for acute non A, non B hepatitis in the United States and association with hepatitis C virus infection. *JAMA*, 264:2231-2235.

- Alter H, Jett B, Polito A, et al. (1991):** Analysis of the role of hepatitis C in transfusion-associated hepatitis. In: Hollinger F, Lemon S, Margolis H (eds): Viral Hepatitis and Liver Disease. Baltimore, Williams & Wilkins:396-402.
- Alter HJ (1991):** The hepatitis C virus in current prospective Ann. Intern. Med., 115:644-649.
- Alter MJ, Margolis HS, Krawczynski K, et al. (1992):** The natural history of community- acquired hepatitis C in the United States. N Eng. J. Med., 327: 1899-905.
- Alter HJ (1995):** To C or not to C: these are questions Blood, 85: 1681-1695.
- Alter MJ. (1997):** Epidemiology of hepatitis C. Hepatology, 26:625, 655.
- Alter MJ, Hutin YJ and Armstrong GL. (2000):** Hepatitis C. San Diego academic press, 189-183.
- Arase Y, Ikeda K, Chayama K, et al. (1999):** Clinical and virological features of chronic hepatitis C carriers with normal alanine aminotransferase levels despite positive serum HCV-RNA after interferon therapy. J Gastroenterol; 34: 594–9.
- Armstrong GL, Alter MJ, Mcguillan GM, et al, (2000):** The past incidence of hepatitis C virus infection. Hepatology, 31:777-782.
- Armstrong GL, Wasly A, Simard EP, et al. (2008):** The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. An intern med, 144:705-714.
- Arora S, O'Brien CB, Zeuzem S, et al. (2006):** Treatment of patients with persistently normal ALT levels with the combination of peginterferon alfa-2a (40 KD) plus ribavirin: impact on health-related quality of life. J. Gastroenterol Hepatol; 21: 406–12.

- Arther RR, Hassan NF, Abdallah MY, et al. (1997):** Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. Transactions of the royal society of tropical medicine and hygiene, 91: 271-274.
- Bach N, Thung SN and Schaffner F (1992):** The histological changes in chronic hepatitis C and autoimmune hepatitis: A comparative analysis. Hepatology, 15 (4): 572-577.
- Bacon BR. (2002):** Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology; 36 (5 Suppl. 1): S179–84.
- Barrett S, Goh J, Coughlan B, et al. (2001):** The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort spontaneous viral clearance and chronic HCV infection. Gut; 49: 423–30.
- Bedossa P and Poynard T. (1994):** The METAVIR Cooperative Group. Inter-and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology; 20(1):15-20.
- Bedossa P and Poynard T. (1996):** For the METAVIR Cooperative Group: An algorithm for the grading of activity in chronic hepatitis C. Hepatology, 24:289-293.
- Bendinelli M, Vatteroni ML, Maggi F, et al. (1999):** Hepatitis C virus. Biology, Pathogenesis, Epidemiology, Clinical Description and Diagnosis. In: Specter, S. ed. Viral Hepatitis: Diagnosis, Therapy, and Prevention. New Jersey: Humana press: 65-127.
- Bianchi L, DeGroot J, Desmet VJ, et al. (1977):** Acute and chronic hepatitis revisited. Lancet; 2: 914-919.

- Bissonette RT, Gibney RG, Berry BR, et al. (1990):** Fatal carcinoid crisis after percutaneous fine-needle biopsy of hepatic metastasis: case report and literature review. *Radiology*; 174:751.
- Bodenheimer HC, Lindsay KL, Coughlan B, et al. (1997):** Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. *Hepatology*, 26:473–7.
- Bond WW, Favero MS, Petersen NJ, et al. (1981):** Survival of hepatitis B virus after drying and storage for one week. *Lancet*, 1:550-551.
- Boniolo M and Davis R. (1982):** Enzyme immunoassay for qualitative determination of HBV antigen and antibodies in Serum. *J. infect. Dis* ; 15-260.
- Boyer JL and Klatskin G (1970):** Pattern of necrosis in acute viral hepatitis: Prognostic value of bridging (subacute hepatic necrosis). *N. Engl. J. Med.*, 283: 1063-1071.
- Bradly, DW, Maynard JE, Popper H, et al. (1983):** Post transfusion non A non B hepatitis: Physicochemical properties of two distinct agents. *J. Infect. Dis.*, 148: 254-265.
- Brien C, Wintfeld N, Patel KK, et al. (2004):** The impact of sustained virological response (SVR) on health-related quality of life (HRQL) in patients with chronic hepatitis C (CHC) and persistently normal ALT levels (PNALT) treated with peginterferon alfa-2a (PEGASY) and ribavirin (COPEGUS). *J. Hepatol*; 40 (Suppl. 1): 147. Abstract 499.
- Brillanti S, Foli M, Gaiani S, et al. (1993):** Persistent hepatitis C viraemia without liver disease. *Lancet*; 341: 464–5.

- Brillanti S, Levantesi F, Nigro G, et al. (2003):** Peginterferon-based therapy for chronic hepatitis C virus infection in patients with normal alanine aminotransferase levels. *Ann. Intern. Med* ; 139: W83.
- Brunt EM, Peters MG, Flye MW, et al. (1992):** Day-5 protocol liver allograft biopsies document early rejection episodes and are predictive of recurrent rejection. *Surgery*; 111:511.
- Bukh J, Purcel RH, and Miller RH. (1992):** Sequence analysis of the 5 non coding region of hepatitis C virus. *Proc. Natl. Acad. Sci. USA*, 89: 4942-4946.
- Bukh J. (1995):** Genitic heterogenicity of hepatis C virus: Quasispecies and genotypes. *Semin. Liver. Dis.*, 15: 41-63.
- Buscarini L, Fornari F, Bolondi L, et al., (1990):** Ultrasound guided fine- needle biopsy of focal liver lesions: techniques, diagnostic accuracy and complications. *J. Hepatol.*; 11:344.
- Busch MP, Glynn SA, Stramer SI, et al. (2005):** New Strategy for estimating risk of transfusion transmitted viral infections based on rates of detection of recently infected donors. *Transfusion*, 45:254-264.
- Castera L, Hezode C, Roudot-Thoraval F, et al.(2003):** Worsening of steatosis is an independent factors of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. *Gut*,52:288–292.
- Cha TA, Kolberg J, Irvine P, et al. (1991):** Use of signature nucleotide sequence of hepatitis C virus for detection of viral RNA in human serum and plasma. *J. Clin. Microbial*, 29: 2528-2534.

- Chan TT, Liau TC, Yaung KC, et al. (1994):** Intrafamilial transmission of hepatitis C virus: The important role of inapparent transmission. *J. Viral. Methods*, 35(3): 343-352.
- Cheney CP, Chopra S and Graham C (2000):** Hepatitis C. *Infectious Disease Clinics of North America*; 14:633-667.
- Choo QL, Kuo G, Weiner AJ, et al. (1989):** Isolation of DNA clone derived from a blood born non A non B viral hepatitis genom. *Science*, 244: 359-362.
- Choo QL, Kuo G, Ralston R, et al. (1994):** Vaccination of chimpanzees against infection by the hepatitis C virus. *Proc. Natl. Acad. Sci. Usa*; 91:1294-8.
- Christoffersen P, Poulsen H and Skeie E. (1970):** Focal liver necrosis accompanied by infiltration of granulocytes arising during operations. *Acta Hepato- Splenologica*; 17:240-245.
- Chung RT and Kalpan LM. (1992):** Isolation and characterization of an HCV specific RNA dependent RNA polymerase activity from extracts of infected liver tissue in: Houghton M, Bonino F, Aquino M. (eds): *Hepatitis C virus and related viruses. Molecular virology and pathogenesis*. 1<sup>st</sup> annual meeting Venice. Abstract A, 15, P. 21.
- Cividini A, Rebucci C, Silini E, et al. (2001):** Is the natural history of hepatitis C virus carriers with normal aminotransferase really benign? *Gastroenterology*; 121: 1526–7.
- Colombo M, del Ninno E, de Franchis R, et al. (1988):** Ultrasound assisted percutaneous liver biopsy: Superiority of the Trucut over the Menghini needle for diagnosis of cirrhosis. *Gastroenterol.*; 95:487.

- Conry-Cantilena C, VanRaden M, Gibble J, et al. (1996):** Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. *N Engl J Med*; 334: 1691–6.
- Darwish MA, Shalecer M, Raslono, et al.(1993):** Hepatitis B and D viral infection among schistosomal patients in Egypt. *J Egypt Public Health Association*, 67(6-6): 549-63.
- Davis GL, Balart LA, Schiff ER, et al. (1989):** Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. Hepatitis interventional therapy Group. *N Engl J Med*. 321:1501-6.
- DeGroot J, Desmet VJ, Gedik P, et al. (1968):** A classification of chronic hepatitis. *Lancet*; 2: 626-628.
- Des Jarlis DC, Diaz T, Perlis T, et al. (2003):** Variability in the incidence of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection among young injecting drug users in New York city. *Am J Epidemiol*, 157:467-471.
- Delladetsima JK, Rassidakis G and Tassopoulos N. (1996):** Histopathology of chronic hepatitis C in relation to epidemiological factors. *J Hepatol*, 24:27-32.
- Desmet VJ, Gerber M, Hoofnagle JH, et al. (1994):** Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology*; 19:1513-1520.
- Desmet V, Roskams T and VanEyken P. (2008):** Ductular reaction in the liver. *Pathol. Res. Pract.*; 191:513-524.
- Deuffic S, Buffat L, Poynard T, et al. (1999):** Modeling the hepatitis C virus epidemic in France *Hepatology*, 29: 1596-1601.

- Di Bisceglie AM. (1999):** Chronic hepatitis C viral infection in patients with normal serum alanine aminotransferases. *Am J Med*; 107 (6B): 53S–5S.
- Dienes HP, Popper H, Arnold W, et al. (1982):** Histological observations in human non-A, non-B. *Hepatology*; 2:552.
- Dienstag JL and Isselbacher KJ.(1998):** Acute hepatitis. In: Isselbacher KJ, Braunwald E, Wilson ID, eds. *Harrison's Principles of Internal Medicine*. 14th Ed. New York: McGraw-Hill; 295:1677-1692.
- Dienstag JL. (2002):** The role of liver biopsy in chronic hepatitis C. *Hepatology*; 36 (1): S152-S160.
- Dienstag and Mchutchison. (2006):** American Gastroenterological Association Technical Review on the Management of Hepatitis C. *Gastroenterology*,130:231–264.
- Dincer D, Okten A, Kaymakogius C, et al. (2003):** Persistently normal alanine transaminase level in chronic C hepatitis what does it tell us. *Hepato. Gastroenterology*, 48: 1397-1400.
- Domingue ZA, Bruguera M, Vidal J, et al. (2001):** Community based seroepidemiological survey of HCV infection in Catalonia, Spain, *J Med Viral*, 65:688-693.
- Donaldson BW, Gopinath R, Wanless IR, et al. (1993):** The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators. *Hepatology*; 18:1370.
- Doumos BT, Waston W and Biggs HG. (1971):** Determination of albumin. *Clin. Chem. Acta*; 31: 87 . Quoted by **Ziyatdinova GK, Budnikov GK and Pogorel'tsev VI.** Determination of serum albumin in blood by constant current coulometer using electrochemically generated oxidizers. *Journal of Analytical Chemistry*, 2004; 59:659-661.

- Druwe PM, Michelsen PP and Raman AM. (1994):** Hepatitis C and nephrology. *Nephrol. Dial. Transplant*, 9:230-237.
- Dubois F, Francois M, Mariotte N, et al. (1994):** Serum alanine aminotransferase measurements a guide to selective testing for hepatitis C during medical checkup. *J. Hepatol*; 21: 837–41.
- Dussol B, Berthezene P, Brunet, et al. (1995):** Hepatitis C virus infection among chronic dialysis patients in the Sauc of France: A collaborative study. *Am. J. Kidney. Dis.*, 25:399-404.
- Duvnjak M, Pavic T, Virovic L, et al. (2003):** Therapy with interferon alfa and ribavirin in patients with chronic hepatitis C and normal levels of alanine aminotransferase. *Acta. Med. Croatica* ; 57: 159–62.
- El.Sayed MN, Gomatos PJ, Rodier GR, et al, (1996): Seroprevalance.** Survey of Egyptian Tounsm Worker for hepatis B virus, HCV, HIV, Treponema Pallidum infection. *AmJ. Top. Med. Hyg*, 55(2): 179-84.
- El-Gohary A, Hassan A, Nomman Z, et al. (1995):** High prevalence of hepatis C virus among urban and rural population group in Egypt. *Acta. Trop*, 59: 155-161.
- El -Gaafary MM, Rekacewicz C, Michelsen PP, et al.(2005):** Surveillance of acute hepatitis C in Cairo, Egypt. *J .Med .Virol*,76:520–5.
- El-Sahly AM, Nour El-Din ME, Abdel Rhman HN, et al .(1991):** Prevalance of anti bodies to HCV in Egyptian patients with schistosomiasis. The 9 National Congress of the Egyptian Society of Hepatology.

- Esteban JI, Cordoba J and Saulead S. (1998):** Hepatitis C: Molecular Biology, pathogenesis, epidemiology, clinical feature and prevention in: Boyer JL, Okner RK (eds). Progress in liver disease. Vol. 10, Philadelphia, W. B. Saunders: 253-282.
- Ewe K, (1981):** Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig. Dis. Sci.; 26: 388.
- Eyster MW, Alter HJ, Aldort LM, et al. (1991):** Heterosexual Co-transmission of hepatitis C virus and human HIV. Ann. Int. Med., 115:764-768.
- Ferni MA, Artuso D, Gerken G, et al. (1995):** Focal lymphocytic aggregates in chronic hepatitis C: occurrence, immunohistochemical characterization and relation to markers of autoimmunity. Hepatology; 22:389.
- Fiorentino DF, Ziotnik A, Viera P, et al. (1991):** IL-10 acts on the antigen presenting cell to inhibit cytokine production by T-helper cells.
- Frank c, Mohamed MK, Strickland GT, et al. (2000):** The role of parenteral antischistosomal therapy, in the spread of hepatitis C virus in Egypt. Lancet, 355 (9207): 887-91.
- Ghany MG, Kleiner DE, Alter H, et al. (2003):** Progression of fibrosis in chronic hepatitis C. Gastroenterology; 124: 97–104.
- Gholson CF, Morgan K, Catinis G, et al. (1997):** Chronic hepatitis C with normal aminotransferase levels: a clinical histological study. Am. J Gastroenterol; 92: 1788–92.
- Gilbert N, Corden S, Ijaz S, et al. (2002):** Comparison of commercial assays for the quantification of HBV DNA load in healthy care workers. J. Virol Methods, 100: 37-47.

- Gordon SC, Fang JW, Silverman AL, et al. (2000):** The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. *Hepatology*; 32: 400–4.
- Grant A and Neuberger J. (1999):** Guidelines on the use of liver biopsy in clinical practice. *British Society Gastroenterology. Gut. Oct;45 Suppl 4:IV1-IV11.*
- Gretch DR. (1997):** Diagnostic tests for hepatitis C. *Hepatology* 26 (Suppl I) 43S-47S. Irish Hepatology research group. *New Engl. J. Med.*, 340:1228-1233.
- Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. (2000):** Efficacy of long term lamivudine monotherapy in patients with HBeAg negative chronic hepatitis B. *Hepatology*; 32:847-51.
- Hadziyannis SJ, Sette H Jr, Morgan TR, et al. (2004):** Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. *Ann Intern Med*; 140: 346–55.
- Hagan H, Snyder N, Haugh E, et al. (2002):** Case reporting of acute hepatitis B and C among injection drug users. *J. Urban Health*, 97:579-585.
- Hagiwara H, Hayashi N, Mita E, et al. (1993):** quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. *Hepatology*, 17:545-550.
- Halfon P, Imbert-Bismut F, Messous D, et al. (2002):** A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. *Comp. Hepatol* ; 1: 3.

- Han JH, Shyamala V and Richman KH. (1991):** Characterizations of the terminal region of hepatitis C viral RNA: Identification of conserved sequence in the 5 untranslated region and poly (A) tail at 3 end. Proc. Natl. Acad. Sci. USA, (88): 1711-1715.
- Hasan F, Asker H, Al-Khalid J, et al. (2002):** Interferon-alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients with persistently normal aminotransferase levels. Digestion;65:127-30.
- Hashimoto E, Ludwig J, MacCarty RL, et al. (1989):** Hepato portal arteriovenous fistula: morphologic features studied after orthotopic liver transplantation. Hum. Pathol.; 20:707.
- Hauri AM, Armstrong GL and Hutin YJ. (2004):** The global burden of disease attributed to contaminated injection given in health care setting. Int. J. STD. AIDS, 15:7-16.
- Hay JE, Czaja AJ, Rakela J, et al. (1989):** The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology; 9:193-197.
- Herrerias JM, Company FP, Osorio M, et al. (1974):** Discrepancias entre el diagnóstico laparoscópico e histológico en la cirrosis hepática. Rev. Esp. Enf. Ap. (Eng. abstract) Digest.; 42:709-714.
- Herve S, Savoye G, Riachi G, et al. (2001):** Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity?. Eur. J. Gastroenterol Hepatol; 13: 495-500.
- Hirsch KR and Wright TL. (2000):** The dilemma of disease progression in hepatitis C patients with normal serum aminotransferase levels. Am. J Med; 109: 66-7.

- Hoballah A and Sabry H. (1996):** Hepatitis C virus infection. Egyptian Military Medical Journal, Vol. 41, No. 2, 14-16.
- Holtz T, Moseley RH, Scheiman JM. (1993):** Liver biopsy in fever of unknown origin: a reappraisal. J. Clin. Gastroenterol.; 17:29.
- Hoofnagle JH, Carithers RL, Shapiro C, et al. (1995):** Fulminant hepatic failure summary of a workshop. Hepatology; 21:240-252.
- Hoofnagle JH. (1997):** Hepatitis C: The clinical spectrum of disease Hepatology; 26(Suppl. 1):15S-20S.
- Howard R, Karageorge G, van Harselaar K, et al. (2008):** Post-procedure surveillance in liver biopsy: how long is long enough?. N.Z. Med J. Aug 22; 121(1280):8-14.
- Hui CK, Belaye T, Montegrando K, et al. (2003):** A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J. Hepatol; 38: 511- 7.
- Hui CK, Monto A, Belaye T, et al. (2003):** Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminase. Gut, 52:1644-1648
- Ideo G, Bellobuono A, Tempini S, et al. (1996):** Poor efficacy of alpha interferon treatment in patients affected by chronic hepatitis C with normal or near normal ALT levels. Gastroenterology; 110: 1215A.
- Ishak K, Baptisa A, Bianchi L, et al. (1995):** Histological grading and staging of chronic hepatitis. J. Hepatol.; 22:696-699. J. Hepatol, 31 (Suppl. 1):9S-16S.
- Jamal M, Soni AP, atrick G , et al. (1999):** Clinical Features of Hepatitis C–Infected Patients. Hepatology, 1999; 30:1307-1311.

- Jamal MM and Abdelkarim BZ. (2003):**Chronic hepatitis C with persistently normal aminotransferase levels: do we have an adequate definition? Am .J .Gastroenterol; 98: 1455–6.
- Kabil SM,El-Zayadi A, Kamel R, et al.(1990):** The true situation of liver disease in Egypt with the beginning of declension of virus B hepatis J. Trop. Med, 1(1): 1-10.
- Kabil SM, Abdel-Hamid M, Constantine N, et al.(1993):**HCV RNA in sera and saliva of Egyptian patients. J. Trop.med, 2(4):1-2.
- Kabil SM, Salwa M Youssef, Hussien AT, et al. (1995):** About HCV in Egypt, J. H. I. D, 3(4): 1-3.
- Kabil SM, Salwa M Youssef, Atta MME, et al. (1996):**High prevalence of hepatitis C virus RNA in saliva of patients with chronic HCV infection.J.H.G.I.D,4(2):1-6.
- Kaito M, Watanabe S, Tsukiyama K, et al. (1994):** Hepatitis C virus detected by immunoelectron microscopy study. J. Gen. Virol., 75:1755-1760.
- Kamel MA, Ghaffar YA, Wasef MA, et al. (1992):** High HCV prevelance in Egyptian blood donors. Lancet, 15 (340): 427.
- Kamel MA, Miller FD, El-Massy AG, et al. (1994):** The epidemiology of schistosoma mansoni, hepatis B and C in Egypt. Annals of Tropical Medicine And Parasitology, 88 (5): 501-9.
- Kamili S, Krawczynski K, mc Caustland KA, et al.(2007):**The infectivity of hepatitis C virus after drying and storing at room temprature.Infect Control hosp epidmol,28:519-524.
- Kamitsaukasa H, Harda H and Yakura M. (1989):** Intrafamilia transmission of HCV. Lancet, 2(8669):987.

- Karamshi M. (2008):** Performing a percutaneous liver biopsy in parenchymal liver diseases. *Br J. Nurs.* Jun.26-Jul 9;17(12):746-52.
- Kato N, Yoshida H, Kioko S, et al. (2000):** Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. *Hepatology*; 32:405-412.
- Keating GM and Plosker GL.( 2005):** Peginterferon alpha-2a (40 KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently ‘normal’ ALT levels. *Drugs*; 65: 521–36.
- Khalifa AS, Mitchell BS, Watt DM, et al. (1993):** Prevalence of hepatitis C viral antibody in transfused and non transfused Egyptian children. *Am. J. Trop. Med. Hyp*, 49 (3): 316-321.
- Kieft, JS, Zhou K, Jubin R, et al. (1999):** The hepatitis C virus internal ribosome entry site adopts an ion-dependent tertiary fold. *J. Mol. Biol.*, 292:513-529.
- Kita H, Moriyama T, Kaneko T, et al. (1995):** A helper T-cell antigen knockout mice: reexamination hepatitis C. In: *Hepatitis C Biochemical Research Reports*. (Liang TJ and Hoofnagle JH, eds.). Academic press, pp. 107-124.
- Kiyosawa K,Sodeyama T and Tanakae.(1994):** Hepatitis C virus infection in health care workers. *Viral hepatitis and liver disease Tokyo:Springer-Verlag*,479-482.
- Klatskin G and Conn HO, (1993):** *Histopathology of the liver*. New York: Oxford University Press.

- Knodell RG, Ishak KG, Black WC, et al. (1981):** Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology*; 1:431-435.
- Koziet MJ, Dudley D, Afdhal N, et al. (1993):** Hepatitis C virus (HCV)-specific cytotoxic T-lymphocyte recognize epitopes in the core and envelope proteins of HCV. *J. Virol*, 7: 7522.
- Kyrlagkitsis I, Portman B, Smith H, et al. (2003):** Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT. *Am J Gastroenterol*, 98:1588-93.
- Labayle D, Chaput JC, Albuissou F, et al. (1979):** Analyse histologique comparative des biopsies du lobe droit et du lobe gauche dans les lésions alcooliques du foie. (Eng. Abstract) *Gastroenterol. Clin. Biol.*; 3:235-240.
- Lau JYN, Davis GL, Kniffen J, et al. (1993):** Significance of serum hepatitis C RNA levels in chronic HCV infection. *Lancet*, 341:1501.
- Lau JYN, Simmonds P, and Urde I. (1995):** Implications of variations of conserved regions of hepatitis C virus genome. *Lancet*, 346:425-426.
- Lauer GM and Walker BD.(2001):** Hepatitis C virus infection. *N .Engl . J Med*; 345:41-52.
- Law MG, Dore GJ, Bath N, et al. (2001):** Modelling hepatitis C virus incidence, prevalence and long term sequelae in Australia. *Int. J. Epidemiol*, 32:717-724.
- Lebrech D. (1996):** Various approaches to obtaining liver tissue: choosing the biopsy technique. *J. Hepatol.*; 25 (suppl. 1):20.

- Lee S. (2000):** Development of a serological test for HCV core protein. New Horizon in HCV screening 29-30. March, CAP (5) 1-3 Quai de Grenelle 75015 Paris, France.
- Leevy CM, Popper H and Sherlock S. (1976):** Diseases of the liver and biliary tract. Standardization of nomenclature, diagnostic criteria and diagnostic methodology. DHEW publication on (NIH); 76-725.
- Lindner H. (1971):** Hazards of percutaneous liver biopsy. Med. Klin.; 66:924.
- Liu C, Lin J, Tsai F, et al. (2006):** Non invasive test for the prediction of significant hepatic fibrosis in hepatitis C virus carrier with persistently normal ALT. Liver international, 26:1087-1094.
- Lo SY, Selby MJ and OV JM. (1996):** Interaction between hepatitis C virus core protein and E1 envelope protein. J. Virol., 70:5177-5182.
- Lok AS and McMahon BJ. (2001):** Chronic hepatitis B. Hepatology; 34:1225-1241
- Ludwig J. (1993):** The nomenclature of chronic active hepatitis: an obituary. Gastroenterol.; 105: 274-27
- Ludewig B, Ehl S, Karrer U, et al. (1998):** Dendritic cells efficiently induce protective antiviral immunity. J. virol, 72:3812-18.
- Maddrey WC. (1991):** Liver biopsy: a 1990s perspective. In: Hoofnagle JH, Goodman Z, eds. Liver Biopsy: Interpretation for the 1990's. Thorofare, N.J., AASLD: 479.
- Major ME and Feinstone SM. (1997):** The molecular virology of hepatitis C. Hepatology,25:1527-1537.

- Mangia A, Spinzi G, Vuturo O, et al.(2004):** Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study. *Aliment Pharmacol Ther*; 19: 331–7.
- Manns MP, McHutchison JG, Gordon SC, et al. (2001):** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. *Lancet*; 358: 958–65.
- Marcellin P, Levy S and Erlinger S. (1997):** Therapy of hepatitis C: patients with normal aminotransferase levels. *Hepatology*, 26 (Suppl. 1): 133S-137S.
- Marcellin P. (1999):** Hepatitis C: The clinical spectrum of the disease.
- Martinot-Peignoux M and Boyer N. (2001):** prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. *Hepatology*; 34: 1000–5.
- Mathurin P, Moussalli J, Cadranel J,F et al. (1998):** Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine tansaminase activity. *Hepatology*, 27:868-872.
- Matsumoto M, Hwang SB, Jeng KS, et al. (1996):** Homotypic interaction and multimerization of hepatitis C virus core protein. *Virology*, 218:43-51.
- McGill DB, Rakela J and Zinsmeister AR. (1990):** A 21 year experience with major hemorrhage after percutaneous liver biopsy. *Gastroenterology* 99:1396.

- Mc-Intyre PG, Mc-cruden EA, Drow BC, et al. (1994):** Hepatitis C virus infection in renal dialysis patients in Glasgow. *Nephrol. Dial Transplant*, 9:291-295.
- Medhat A, Shehata M, Magder LS, et al. (2002):** Hepatitis C in community in upper Egypt and risk factors for infection. *Am. J. Trop.Med. Hyg*, 66:633-638.
- Minuk GY, Sutherland LR, Wiseman DA, et al. (1987):** Prospective study of the incidence of ultrasound-detected intrahepatic and subcapsular haematomas in patients randomized to 6 or 24 hr of bed rest after percutaneous liver biopsy. *Gastroenterol.*; 92:290.
- Missale G, Bertoni R, Lamonaca V, et al. (1996):** Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. *Jclin. Invest*, 98:706-714.
- Mohammed Mk, Abdel-Hamid M, Mikhail NN, et al. (2005):** Intrafamilial transmission of hepatitis C in Egypt. *Hepatology*, 42:683-687.
- Moretta L, Ciccone E, Mingari MC, et al. (1994):** Humman natural killer cells: origin, clonality, specificity and, receptors. *Avi. Immunol*, 55: 341-58.
- Morisco F, Del Vecchio Blanco G, TuccilloC, et al . (1998):** Long-term observation of HCV-positive patients with normal ALT values: persistence of a clinically healthy state. *Res. Virol*; 149: 277–82.
- Muller HM, Pfaff E, and Goeser T. (1993):** Peripheral blood leukocytes serve as a possible extra-hepatic site for hepatitis C virus replication. *J. Gen. Virol.*, 74:669-676.

- Murray JM, Law MG, Gao Z, et al. (2003):** The impact of behavioural changes on the prevalence of human immuno-deficiency virus and hepatitis C among injecting drug users. *Int. J. Epidemiol*, 32: 708-714.
- Nagayoma R, Miyake K, Tsuda F, et al., (1994):** IgM antibody to a hepatitis C virus core peptide (CP14) for monitoring activity of the disease. *J. Virol.*,68: 4420.
- National Institutes of Health. (1997):** Panal statement: Management of hepatitis C *Hepatology*, Vol. 26, No. 3, suppl. 1:25-105.
- National Institutes of Health Consensus. (2002):** Development Conference Statement: management of hepatitis C: 2002– June10–12, 2002. *Hepatology*; 36 (5 Suppl. 1): S3–2.
- Nelson DR, Marousis CG, Davis GL, et al. (1997):** The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. *J. Immunol*, 158:1473.
- Niu MT, Coleman, PJ, Alter MJ, et al. (1993):** Multicenter study of hepatitis C virus infection in chronic haemodialysis patients and hemodialysis center staff members. *Am. J. Kidney, Dis.*, 22:568-573.
- Nutt AK, Hassan AK, Lindsay J, et al. (2000):** Liver biopsy in the evaluation of patients with CHC who have repeatedly normal or near normal serum ALT levels. *Am .J .Med*, 109:62-4.
- Ogasawara S, Kage M and Kosal KI. (1993):** HCV RNA in saliva and breast milk of hepatitis C cancer mother. *Lancet*, 341:561-563.
- Ohato H, Terzawa S and Sasaki N, et al. (1994):** Transmission of hepatitis C virus from mothers to infants. *N. Engl, J. Med.*, 330:747-750.

- Ohata K, Hamasaki K, Toriyama K, et al. (2003):** Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. *Cancer*,97:3036–3043.
- Okanoue T, Yasui K, Sakamoto S, et al. (1996):** Circulating HCV-RNA HCV genotype, and liver histology in asymptomatic individuals reactive for anti-HCV antibody and their follow-up study. *Liver*; 16: 241–7.
- Okanoue T, Makiyama A, Nakayama M, et al. (2005):** A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. *J. Hepatol*; 43: 599–605.
- Okanoue T, Itoh Y, Minami M, et al. (2008).** Guidelines for the antiviral therapy oh hepatitis C. virus carriers with normal serum aminotransferase based on platelet count. *Hepatology researches* 38:27-36.
- Okayama A, Stuver SO, Tabor E, et al. (2002):** Incident hepatitis C virus infection in a community-based population in Japan, *J. Hepatol* 55:44-49.
- Oxenius A, Zinkernagel RM and Hengartner H (1998):** CD4+T-cell induction and effector function: a comparison of immunity against soluble antigens and viral infection. *Adv. Immunol*, 70:313-670.
- Pagliari L, Rinaldi F, Craxi A, et al. (1983):** Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. *Dig. Dis. Sci.*; 28:39-43.
- Paul Ehrlich (1833):** Quoted by Sherlock and Dooley, (2002).

- Pereira BJ, Milford EL and Kirkman RL. (1992):** Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. *N. Engle. J. Med.*, 327:910-915.
- Perrillo RP. (1997):** The role of liver biopsy in hepatitis C. *Hepatology*; 26: 57-61.
- Persico M, Persico E, Suozzo R, et al. (2000):** Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. *Gastroenterology*; 118: 760–4.
- Persico M, Persico E, Suozzo R, et al. (2000):** Natural history of hepatitis C virus carriers With persistently normal aminotransferase levels. *Gastroenterology*; 118:760-764.
- Perz JF and Alter MJ. (2006):** The coming wave of HCV related liver disease. *J. Hepatology*, 44:441-443.
- Perz JF, Armstrong GL, Farrington LA, et al. (2006):** The concentration of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer world wide. *J. hepatol*, 45:529-538.
- Peterson, J, Green G, Lida K, et al. (2000):** Detection of hepatitis C core antigen in the antibody negative "Window" phase of hepatitis C infection *Vox. Sang*, 78 (2): 80-85 (Medline).
- Petz D, Klauck S, Rohl FW, et al. (2003):** Feasibility of histological grading and staging of chronic viral hepatitis using specimens obtained by thin-needle biopsy. *Arch Virchows*; 442:238-244.
- Piccinino F, Sagnelli E, Pasquale G, et al. (1986):** Complications following percutaneous liver biopsy: a multicentre retoroscopic study on 68, 276 biopsies. *J. Hepatology*; 2: 165.

- Piton A, Poynard T, Imbert-Bismut F, et al. (1998):** Factors associated with serum alanine transaminase activity in healthy: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. *Hepatology*; 27: 1213–9.
- Polyak SJ and Gretch DR. (1996):** Molecular diagnostic testing for viral hepatitis: methods of application. In: Wilson RA, ed. *Viral hepatitis diagnosis, treatment, and prevention* New York: Marcel Dekker, 1-33.
- Poniachik J, Bernstein DE, ReddyKR, et al. (1996):** The role of laparoscopy in the diagnosis of cirrhosis. *Gastrointest. Endosc.*; S571.
- Poynard T, Bedossa P and Opolon P. (1997):** Natural history of liver fibrosis progression in patients with chronic hepatitis C. *Lancet*, 349:825- 832.
- Poynard T, Deuffic S and Valleron AJ. (1999):** Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe *J. Viral hepatitis*, 6: 411-443.
- Poynard T, Ratziu V and Bedossa P. (2000):** Appropriateness of liver biopsy. *Can. J. Gastroenterol.*; 14:543-548.
- Poynard T, Bedossa P and Opolon P. (2002):** Natural history of liver fibrosis progression in patients with chronic hepatitis C. *lancet*, 349:825-832.
- Poynard T, Yuen MF, Ratziu V, et al. (2003):** Viral hepatitis C. *Lancet*, 362:2095-100.
- Poynard T, Imbert-Bismut F and Ratziu V. (2004):** Serum markers of liver fibrosis. *Hepatology reviews*, 1:23-31.

- Poynard T, Imbert-Bismut F, Munteanu M, et al. (2004):** Over view of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. *Comp. Hepatol* ; 3: 8.
- Pradat P, Alberti A, Poynard T, et al. (2002):** Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. *Hepatology*, 36:973-7.
- Prati D, Capelli C, Silvani C, et al. (1997):** The incidence and risk factors of community acquired hepatitis C in a cohort of Italian blood donors. *Hepatology*; 25:702-704.
- Prati D, Taioli E, Zanella A, et al. (2002):** Updated definitions of healthy ranges for serum alanine aminotransferase levels. *Ann. Intern. Med*; 137: 1–10.
- Prati D, Shiffman M, Diago M, et al. (2004):** How normal are ‘normal’ alanine aminotransferase (ALT) levels in patients with chronic hepatitis C? Data from the randomized, multinational peginterferon alfa-2a (40 KD) (PEGASYS) plus ribavirin (COPEGUS) trial in patients with persistently normal ALT levels [Abstract 532]. *Hepatology*; 40(Suppl. 1): 395 26: 1393–8.
- Prati D, Mitchell L, Diago M, et al. (2006):** Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. *Journal of hepatology*, 44: 679-685.
- Puoti C, Magrini A, Stati T, et al. (1997):** Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine aminotransferase levels. *Hepatology*; (26): 1393-8.

- Puoti C, Bellis L, Martellino F, et al. (2000):** Long-term observation of HCV-positive patients with normal ALT values: persistence of a clinically healthy state. *Res. Virol* ; 149: 277–82.
- Puoti C, Castellacci R, Montagnese F, et al. (2002):** Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). *J. Hepatol*; 37: 117–23.
- Puoti C. (2003):**HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy. *J. Hepatol* ; 38: 529–32.
- Puoti C, Bellis L, Castellacci R, et al. (2004):**. HCV carriers with persistently normal aminotransferase levels. *Hepatology*; 40: 266–7; author reply 267–8.
- Puro V, Petrosillo N and Ippolito G. (1995):** Risk of hepatitis C seroconversion after occupational exposure in health care worker: Italian study group on occupational risk of HIV and other Blood born infections. *Am. J. Infect. Control*, 23:273-277.
- Quer J and Esteban JI. (1997):** Epidemiology and prevention of hepatitis C virus infection hepatitis C 1997: Essay, Diagnosis and Therapy. Abbott Diagnostics Division, 26-38.
- Quinity, El-Gassani, Divizia, M. et al. (1995):** Seroprevalence of HCV infection in Alexandria, Egypt. *Zentralblatt für Bakteriologie*, 283(2):239-244.
- Rasenack J, Zeuzem S, Feinman SV, et al.(2003):** peginterferon alpha 2a (40KD)[Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. *Pharmacoeconomics* ; 21: 341–9.

- Ray R, Khanna A, Legging ML, et al. (1994):** Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus. *J. Hepatol.*, 21 : 403-5.
- Regev A, Berho M, Jeffers LJ, et al. (2002):** Sampling error and intra observer variation in liver biopsy in patients with chronic HCVinfection. *Am. J. Gastroenterol.*; 97:2614-2618.
- Reiser M, Marousis CG, Nelson DR, et al. (1997):** Derum inierleukin 4 Resistant tennis elbow as a nerve entrapment. *J Bone*, (21): 403-5.
- Renou C, Halfon P, Pol S, et al.(2002):** Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. *Gut*, 51 (4):585-90.
- Roberts EA and Yeung L. (2002):** Maternal infant transmission of hepatitis C virus infection. *Hepatology*, 636:1065-1135.
- Rossini A, Ravaggi A, Agostinelli E, et al. (1997):** Virological characterization and liver histology in HCV positive subjects with normal and elevated ALT levels. *Liver*; 17: 133–8.
- Roth D, Zucker K, Cirocco R, et al. (1996):** A prospective study of hepatitis C virus infection in renal allograft recipient. *Transplantation*, 61(6): 886-9.
- Rumi MG, De Filippi F, Donato MF, et al. (2002):** Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. *J. Viral. Hepat*; 9: 71-4.
- Rumi MG, De Filippi F, La Vecchia C, et al. (2005):** Hepatitis C reactivation in patients with chronic infection with genotypes 1b

and 2c: a retrospective cohort study of 206 untreated patients. Gut: 402-6.

**Saadeh S, Cammell G, Carey WD, et al, (2001):** The role of liver biopsy in chronic hepatitis C. Hepatology.33:196-200.

**Sandra LHA (1995):** In: text book of diagnostic ultrasonography 4<sup>th</sup> edition by Sandra LHA (ed) USA Philadelphia , Chapter I, P. 41 Chapter 7, P. 195, Chapter 10, P. 287.

**Schupfer. (1907):** Quoted by Sherlock and Dooley, (2002).

**Scheuer PJ. (1991):** Classification of chronic viral hepatitis: a need for reassessment. J. Hepatol.; 13:372-374.

**Scheuer PJ, Ashrafzadeh P, Sherlock S, et al. (1992):** The Pathology of hepatitis C. Hepatology; 15:567.

**Seeff LB (1997):** Natural history of hepatitis C. Hepatology; 26(Suppl. 1): 21S-28S.

**Serfaty L, Chazouilleres O, Pawlotsky JM, et al. (1996):** Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology ; 110: 291–5.

**Shakil AO, Conry-Cantilena C, Alter HJ, et al. (1995):** Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann. Intern. Med; 123: 330–7.

**Shepard CW, Finelli L, Fiore AE, et al. (2005):** Epidemiology of hepatitis B and hepatitis C virus infection in united states children. Pediatr Infect. Dis. J.; 24:755-760.

- Sherlock S and Dooley J. (1997):** Diseases of the liver and Biliary system. Tenth edition. Blackwell scientific publication, pp 274-294. Children. Pediatr. infect. Dis. J, 24:755-760.
- Sherlock S and Dooley J. (2002):** Anatomy and function; Biopsy of the liver and hepatic cirrhosis. In Diseases of the liver and Biliary system "11<sup>th</sup> Edition", Blackwell Sc. Publ., Oxford, London, Edinburgh, (1): 1-16; (3): 37-44 and (21): 365-377.
- Sherlock S, Dick R and Van Leeuwen DJ. (1984):** Liver biopsy today. The Royal Free Hospital experience. J. Hepatol.; 1:75.
- Shi L, Kraut RP, Aebersold R, et al. (1992):** A natural killer cell granule protein that induces DNA fragmentation and apoptosis. Ann. Intern Med., 119: 311-12.
- Shiffman ML, Stewart CA, Hofmann CM, et al. (2000):** Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J. Infect. Dis 2000; 182: 1595–601.
- Shimotohno K. (2000):** Modulation of cell proliferation by HCV core protein. New Horizons in HCV screening 29-30 March, CAP 15, 1-3 Quai de Grenelle 75015 Paris, France.
- Shindo M, Arai K, Sokawa Y, et al. (1995):** The virological and histological states of anti-hepatitis C virus-positive subjects with normal. Ann Intern Med, 122:586-91.
- Shukla DD, Hoyne PA and Ward CW. (1995):** Evaluation of complete genome sequences and sequences of individual gene products for the classification of hepatitis C viruses. Arch. Virol., 140:1747-1761.

- Simon N, Caurouce AM, Lemarrec N, et al. (1994):* A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. *Kidney. Int.*, 46(2): 504-511.
- Skidmore SJ, Collingham KE and Drake M. (1994):* Sexual transmission of HCV. *J. Med. Virol*, 42:247-248.
- Smith DB, Mellor J, and Jarris LM, et al. (1995):** Variation of the hepatitis C virus 5 non-coding region: Implication for secondary structure, virus detection and typing. *J. Gen. Virol*; 76:1749-1761.
- Spada E, Mele A, Ciccozzi M, et al. (2001):* Changing epidemiology of parenterally transmitted viral hepatitis results from the hepatitis surveillance system in Italy. *Dig liver disease*, 33:778-784.
- Stanley AJ, Haydon GH, Piris J, et al.(1996):* Assessment of liver histology in patients with hepatitis C and normal transaminase level *Eur. J .Gastroenterol Hepatol*.8:869-872.
- Sterling RK, Stravitz RT, Luketic VA ,et al. (2004):* A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. *Clin Gastroenterol Hepatol*; 2: 469–73.
- Strader DB, Wright T, Thomas DL, et al. (2004):* Diagnosis, management and treatment of hepatitis C. *Hepatology*;39: 1147–71.
- Takahashi M, Yamada G, Miyamoto R, et al. (1993):* Natural course of chronic hepatitis C. *Am J Gastroenterol*; 88: 240-243.
- Takehara T, Hayashi N, and Mita E. (1992):* Detection of minus strand of hepatitis C virus RNA by reverse transcription and polymerase chain reaction: Implication for hepatitis C virus replication in infected tissue. *Hepatology*, 15(3): 387-390.

- Tassopoulos NC.(1999).** Treatment of patients with chronic hepatitis C and normal ALT levels. *J Hepatol*;31(Suppl 1):193-19.
- Tassopoulos NC, Vafiadis I, Tsantoulas D, et al. (2002):** IFN-alpha 2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized controlled study. *J. Interferon Cytokine Res.*; 22: 365–9.
- Theodossi A, Spiegelhalter D, Portmann B, et al. (1983):** The value of clinical, biochemical, ultrasound and liver biopsy data in assessing patients with liver diseases. *liver*; 3:315-326.
- Thrope LE, Quellet LT, Hershov R, et al. (2002):** Risk of hepatitis C virus infection among young adult injection drug users who share injection equipments. *Am. J. Epidimiol*, 155:645-653.
- Tobin MV and Gilmore IT. (1989):** Plugged liver biopsy in patients with impaired coagulation. *Dig. Dis. Sci.* 34:13.
- Tobkes AI and Nord HJ. (1995):** Liver biopsy: review of methodology and complications. *Digestion*; 13:267.
- Tsai SL, Chen PJ, Hwang LH, et al. (1994):** Immune response to a hepatitis C nonstructural protein in chronic hepatitis C virus infection. *J. Hepatology*, 21:403.
- Tseuji K, Yamasaki K and Yamanishi C. (2001):** RNA carriers: a 10-year follow-up study. *J. Gastroenterol Hepatol*; 16: 536–40.
- Valla D and EASL Jury. (2003):** EASL international consensus conference on hepatitis B. *J. Hepatol.*; 38:533-540.
- Van Doorn LJ. (1994):** Review molecular biology of the hepatitis C virus. *J. Med. Virol.*, 43:345-356.

- Vander Poel Cl, Cuypers HT and Reesink HW. (1994):** Hepatitis C virus six years on. *Lancet*. 344: 1475-1479.
- Van Thiel DH, Caraceni P, Molloy PJ, et al. (1995):** Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy. *J. Hepatol*; 23:503-8.
- Veneri RJ, Gordon SC and Fink-Bennett D. (1989):** Scintigraphic and culdoscopic diagnosis of bile peritonitis complicating liver biopsy. *J. Clin. Gastroenterol*; 11:571.
- Villeneuve JP, Bilodeau M, Lepage R, et al. (1996):** Variability in hepatic iron concentration measurement from needle biopsy specimens. *J. Hepatol.*; 25:172.
- Wang C, and Siddique A. (1995):** Structure and function of hepatitis C internal ribosome entry site. *Curr. Trop. Microbiol.*, 203:99-115.
- Wassim H, Shaker W, Sherif A, et al. (1996):** Prevalance of hepatitis C virus in Egypt. *Hepatology*, 25(1): 167.
- Westin J, Lagging LM, Wejstal R, et al. (1999):** Inter-observer study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. *liver*; 19:183-187.
- Whitmire LF, Galambos JT, Philips VM, et al. (1985):** Imaging guided percutaneous hepatic biopsy: diagnostic accuracy and safety. *J. Clin. Gastroenterol.*; 7:511.
- Williams IT, Perz JF and Bell BP. (2004):** Viral hepatitis transmission in ambulatory health care settings. *CLin. Infect. Dis*, 38:1592-1598.

- World Health Organization (1993):** The central of schistosomiasis. 2<sup>nd</sup> report of WHO expert committee. WHO Tech. Rep. Ser., 930:70-71.
- Wreghitt TG, Gray JJ and Allain JP. (1992):** Transmission of hepatitis C virus by organ transplantation in the united kingdom. J. Hepatol; 20:768-722.
- Yano M, Kumada H, Kage M, et al. (1996):** The long-term pathological evolution of chronic hepatitis C. Hepatology; 23:1334-1340.
- Young K K Y and Reesick R M. (1993):** Detection of hepatitis C virus RNA by a combined reverse transcription polymerase chain reaction assay. J. Clin. Microbiol.; 31:882-886.
- Yuki N, Hayashi N, Takehara T, et al.(1994):** Serum hepatitis C virus RNA levels and liver injury in volunteer blood donors. Am. J. Gastroenterol; 89: 1462–6.
- Zakim D and Boyer TD. (1996):** Fibrosis representative molecular elements, a basic concept, and emerging targets for suppressive treatment, Hepatic fibrosis and cirrhosis and Evaluation of liver function. In Hepatology. A textbook of liver disease, 3<sup>rd</sup> ed., Library of Congress, USA. (15): 465-498, (16):506-520 and (28):782-825.
- Zeuzem S, Diago M, Gane E, et al. (2004):** Peg interferon alpha-2α(40 KD) and ribavirin in patients with chronic hepatitis C and normal aminotransferase level. Gastro-entology, 127:1724-32.
- Zeuzem S, Alberti A, Rosenberg W, et al. (2006):** Management of patients with chronic hepatitis C virus infection and normal alanine aminotransferase activity. Alimentary pharmacol and therapeutic, 24:1133-1149.

## *References*

---

*Zhang M, Sun XD, Mark SD, et al. (2005):* Hepatitis C virus infection, Linxian and China. *Emerg. Infect. D.S*, 11:17-21.

*Zhu N, Khoshnan A, Schneider R, et al. (1998):* Hepatitis C virus core protein binds to the cytoplasmic domain of tumour necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. *J. Virol.*, 72:3691-3697.